Friedreich Ataxia (FA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Friedreich ataxia, a rare hereditary condition, initiates its course during childhood and results in a gradual nervous system deterioration, along with motor function impairments. Approximately 25% of individuals affected by Friedreich ataxia experience an unconventional variant where symptoms manifest after age 25. This disorder predominantly affects European, Middle Eastern, or North African individuals and is infrequently observed in other ethnic populations. The primary genetic cause of Friedreich ataxia typically stems from a recessive inheritance pattern attributed to an expansion mutation of GAA repeats located within the first intron of the FXN gene. This mutation leads to a significant reduction in the production of the frataxin protein. Consequently, the absence of frataxin within cells results in diminished activity of mitochondrial iron-sulfur cluster-containing enzymes, iron accumulation in the mitochondrial matrix, heightened susceptibility to oxidative stress, and impaired adenosine triphosphate (ATP) production. Over time, these cellular disruptions contribute to the progression of the disease's debilitating symptoms.

·       The incidence of Friedreich ataxia in the USA ranges between 2.5 to 3.7 cases per 100,000 population.

 

Thelansis’s “Friedreich Ataxia (FA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Friedreich Ataxia (FA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Friedreich Ataxia (FA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Friedreich Ataxia (FA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Friedreich Ataxia (FA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Friedreich Ataxia (FA), Friedreich Ataxia (FA) market outlook, Friedreich Ataxia (FA) competitive landscape, Friedreich Ataxia (FA) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)